U.S. Marine and Shipping Stock News

In the last week, the market has been flat, but it is up 21% over the past year with earnings expected to grow by 18% per annum over the next few years. In this environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong internal confidence and alignment with shareholder interests.

Over the last 7 days, the United States market has remained flat, though it has risen 21% over the past year with earnings forecasted to grow by 18% annually. The term 'penny stocks' might feel like a relic of past market eras, but the potential they represent is as real as ever. Typically referring to smaller or relatively new companies, these stocks can provide a mix of affordability and growth potential when paired with strong financials.

In the last week, the United States market has been flat, yet it remains up 21% over the past year with earnings forecasted to grow by 18% annually. In this environment, dividend stocks can offer a compelling opportunity for investors seeking steady income and potential capital appreciation.

Investors who take an interest in Greenfire Resources Ltd. ( NYSE:GFR ) should definitely note that the Independent...

With the business potentially at an important milestone, we thought we'd take a closer look at NRx Pharmaceuticals...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Despite the fact that American Coastal Insurance Corporation's (NASDAQ:ACIC) value has dropped 12% in the last week...

Crown Castle stock has fallen sharply over the past five years, yet both its Discounted Cash Flow (DCF) intrinsic value estimate and market multiples currently point to the shares trading at a discount to fundamentals, setting up a clear valuation debate after a difficult stretch for investors. Crown Castle's share price has declined 49.7% over the past five years, which means anyone who bought and held through this period has seen a substantial capital loss that now frames how attractive...

Eos Energy Enterprises secured a contract with the U.S. Department of War to deploy its American-made Z3 zinc-based long-duration energy storage technology. The project will support the Golden Dome for America national defense initiative focused on grid resilience and critical infrastructure. The agreement places Eos technology within U.S. defense and energy supply chains under a government-backed program. Eos Energy Enterprises, listed as NasdaqCM:EOSE, is moving into a new arena with this...

Columbia Threadneedle, part of Ameriprise Financial, has launched new actively managed ETFs focused on premium income and derivative income strategies. Johnson Stivender Wealth Advisors, a large advisory team previously at Raymond James, has joined the Ameriprise Financial platform. Ameriprise Financial (NYSE:AMP) is adding fresh product options and more advisor capacity at the same time, giving investors and clients additional ways to access its platform. The stock recently closed at...

FDA accepts BioMarin Pharmaceutical's supplemental New Drug Application for VOXZOGO for children with achondroplasia. Submission is based on extensive long-term safety and efficacy data from VOXZOGO treatment. The filing aims to convert VOXZOGO's existing authorization into full approval and address a major post marketing requirement. For BioMarin Pharmaceutical (NasdaqGS:BMRN), the FDA's acceptance of the VOXZOGO sNDA centers attention on its rare disease focus and its role in...

Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) value has fallen 11% in the last week, but insiders who sold US$2.8m worth...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Cars.com Inc. ( NYSE:CARS ), is not the largest company out there, but it received a lot of attention from a...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Earlier this month, Vera Therapeutics received FDA accelerated approval for TRUTAKNA (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression, based on interim Phase 3 data from the ongoing ORIGIN 3 trial. The approval makes TRUTAKNA the first therapy to target both BAFF and APRIL in IgA nephropathy, offering a differentiated mechanism via a once-weekly, self-administered autoinjector and underscoring Vera’s growing regulatory and...

Hesai Group (HSAI) is in focus after shareholders approved an 8-for-1 stock split at the June annual meeting, effective July 10, 2026, along with updates on its lidar role with Mercedes-Benz. See our latest analysis for Hesai Group. The stock split and Mercedes-Benz lidar partnership arrive after a mixed run for Hesai Group, with the share price down 15.6% over 30 days and 34.2% year to date. However, a 3 year total shareholder return of 34.1% points to earlier momentum that has since...

Chemours stock has delivered a strong 51.1% gain year to date, yet its valuation checks still suggest the shares lean cheap rather than stretched after that run. Year to date, Chemours is up 51.1%, which puts recent weakness into context for investors weighing whether the move has already priced in the good news. Expectations around how Chemours can convert demand trends in its end markets into durable cash flows, while managing environmental and regulatory risks linked to its operations,...

UWM Holdings (UWMC) is back in focus after losing its bid to acquire Two Harbors Investment, as shareholders of Two Harbors approved a competing all cash offer from CrossCountry Mortgage. See our latest analysis for UWM Holdings. UWM Holdings’ recent setback on the Two Harbors deal comes after a sharp reset in sentiment, with the stock’s 30 day share price return down 13.6% and the year to date share price return down 54%, while the 1 year total shareholder return has declined 46.3%. This...

On July 7, 2026, activist investor Reference Equity released a letter and presentation to CBIZ’s Board, urging the company to halt share repurchases, resume its acquisition program, and raise equity capital to reposition the business for future growth. This intervention puts CBIZ’s capital allocation under the spotlight, questioning whether buybacks or renewed deal-making are better aligned with its growth ambitions. We’ll now examine how Reference Equity’s push to suspend buybacks and...

GE HealthCare Technologies has had a difficult year so far, with the stock down 23.7% year to date, yet both its Discounted Cash Flow (DCF) intrinsic value estimate and market multiples currently point to the shares trading at a discount. Recent headlines ranging from a prostate cancer research collaboration with Mayo Clinic to securities law investigations frame a valuation story that sits between long term potential in precision oncology and heightened risk perception. The share price has...

Skyworks Solutions has seen its share price fall about 65.6% over the past five years, yet current valuation checks suggest the stock now leans cheap relative to its estimated intrinsic value and earnings multiples. With a Discounted Cash Flow (DCF) estimate pointing to roughly 14.5% upside and market-based multiples also screening as undervalued, the key tension is whether this discount reflects opportunity or persistent concern about the business outlook. The share price decline of about...

The Morning Bull - US Market Morning Update Thursday, Jul, 16 2026 US stock futures are pointing higher this morning, with E-mini S&P 500 contracts up about 0.2%, as investors react to a rare piece of good news on inflation. Consumer prices fell 0.4% in June and core inflation, which strips out food and energy, was flat at 2.6% over the past year. In plain terms, the cost of living stopped climbing for a month and underlying pressures cooled. That helped pull the 10 year Treasury yield to...

In recent years, Brookfield Corporation has expanded its insurance platform to more than US$180 billion in assets through acquisitions and outlined plans to grow this to US$350 billion by 2030 via additional deals and organic growth. An interesting development is that Brookfield expects its wealth solutions and insurance platform to account for roughly one‑third of its total earnings growth and to underpin a very large compound annual earnings increase through 2030, signaling a meaningful...